-

IonQ Investor News: Robbins LLP is Investigating IonQ, Inc. (IONQ) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating IonQ (NYSE: IONQ) and its officers and directors to determine whether they breached their fiduciary duties or violated securities laws by failing to disclose material information about the development and effectiveness of its computers to shareholders. IonQ purports to "develop quantum computers designed to solve the world's most complex problems."

If you would like more information about our investigation of IonQ, Inc.'s misconduct, click here.

What is this Case About: According to the complaint, on September 30, 2021, IonQ became a public entity via business combination with dMY Technology Group, Inc. III, a special purpose acquisition company. On May 3, 2022, Scorpion Capital released a research report alleging, among other things, that IonQ is a “scam built on phony statements about nearly all key aspects of the technology and business.” It further claimed that the Company reported “[f]ictitious ‘revenue’ via sham transactions and related-party round-tripping.” On this news, the Company’s stock fell $0.71, or 9%, to close at $7.15 per share on May 3, 2022, on unusually heavy trading volume.

During the class period, defendants failed to disclose to investors that: (1) IonQ had not yet developed a 32-qubit quantum computer; (2) the Company’s 11-qubit quantum computer suffered from significant error rates, rendering it useless; and (3) IonQ’s quantum computer is not sufficiently reliable, so it is not accessible despite being available through major cloud providers. Defendants also failed to disclose that a significant portion of IonQ’s revenue was derived from improper round-tripping transactions with related parties.

Next Steps: If you acquired shares of IonQ, Inc. (IONQ) securities between March 30, 2021 and May 2, 2022, you have legal options. Contact Robbins LLP for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against IonQ, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:IONQ

Release Summary
IonQ, Inc. (IONQ) may have failed to disclose material information about the development and effectiveness of its computers to shareholders.
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Ostin Technology Group Co., Ltd. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ostin Technology Group Co., Ltd. (NASDAQ: OST) ordinary shares between May 11, 2025 and June 26, 2025. Ostin purports to be a manufacturer of thin-film transistor liquid crystal display modules and polarizers used in consumer electronics, commercial LCD displays, and automotive displays. For more information, submit a form, email attorney Aaro...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the REGENXBIO, Inc. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800)...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...
Back to Newsroom